Amgen paying $71 million for misleading promotion of drugs
California-based drugmaker Amgen has agreed to pay $71 million to 48 states, including Pennsylvania, New Jersey and Delaware, and the District of Columbia, to settle allegations that it violated consumer protection laws with misleading promotion of the anemia drug Aranesp and the plaque psoriasis drug Enbrel.
California-based drugmaker Amgen has agreed to pay $71 million to 48 states, including Pennsylvania, New Jersey and Delaware, and the District of Columbia, to settle allegations that it violated consumer protection laws with misleading promotion of the anemia drug Aranesp and the plaque psoriasis drug Enbrel.
Pennsylvania is likely to get about $2.4 million of the total, accoring to the Attorney General's Office. The New Jersey Attorney General's Office said that state would get about $1.57 million.
A spokesman for the Delaware Department of Justice said that state will receive $747,731.78, with the money going to the state's Consumer Protection Fund that "pays for the attorneys, investigators and activities of the unit that pursues consumer cases on behalf of Delawareans at both the national and local level."
In the federal portion of the investigation, Amgen pleaded guilty in 2012 to one count of misbranding Aranesp, and agree to pay $762 million in criminal and civil penalties.
215-854-4506
@phillypharma